2006/026 NICE issues draft guidance on trastuzumab (Herceptin) for early breast cancer

NICE has today (Friday 9 June 2006) published draft guidance on Herceptin, just two weeks after the drug was licensed by the regulatory authorities for use in early breast cancer. The draft guidance recommends the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function. Final guidance is expected to be issued at the beginning of July 2006, assuming there are no appeals.